1 2	Nasopharyngeal Carcinoma and Head and Neck Cancer in Patients with Type-2 Diabetes Mellitus receiving SGI T2L DPP4L or GLP1a: A population-based cohort study
3	
4	Lifang Li PhD ¹ *, Oscar Hou In Chou MSc ² *, Kar Kei Mak ³ , Yifan Yang PhD ⁴ , Cheuk To Chung
5	^{5,6} , Guoliang Li MD PhD ⁷ , Catherine Chan MBChB FRCS ⁸ , Wing Tak Wong PhD ⁹ , Tong Liu
6	MD PhD ¹⁰ , Bernard Man Yung Cheung PhD FRCP ² , Gary Tse MD PhD FRCP FFPH ^{10, 11, 12} #,
7	Jiandong Zhou PhD ^{13,14} #
8	
9	¹ Department of Biostatistics & Health Informatics, Institute of Psychiatry, Psychology &
10	Neuroscience, King's College London, London, United Kingdom
11	² Division of Clinical Pharmacology and Therapeutics, Department of Medicine, LKS Faculty
12	of Medicine, The University of Hong Kong, Hong Kong, China
13	³ School of Medicine, Shanghai Jiao Tong University, Shanghai, China
14	⁴ School of Management, Xi'An Jiao Tong University, Xi'an, China
15 16	⁵ Diabetes Research Unit, Cardiovascular Analytics Group, PowerHealth Research Institute, Hong Kong, China
17	⁶ Cancer Research Institute, Quest Genomics, Hong Kong, China
18	⁷ Department of Cardiovascular Medicine, The First Affiliated Hospital of Xi'an Jiaotong
19	University, Xi'an, China
20	⁸ Department of Ear, Nose and Throat, Prince of Wales Hospital, Hong Kong, China
21	⁹ School of Life Sciences, Chinese University of Hong Kong, Hong Kong, China
22	¹⁰ Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department
23	of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University,
24	Tianjin 300211, China
25	¹¹ Kent and Medway Medical School, Canterbury, Kent, CT2 7NT, United Kingdom
26	¹² School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong,
27	China
28	¹³ Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The
29	University of Hong Kong, Hong Kong, China
30	¹⁴ Division of Health Science, Warwick Medical School, University of Warwick, Coventry,
31	United Kingdom
32	*Co first outbors
33 34	# Correspondence to:
35	Prof. Gary Tse, MD, PhD, FRCP, FFPH
36 37	Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China
38	Kent and Medway Medical School, Canterbury, United Kingdom
39	School of Nursing and Health Studies, Hong Kong Metropolitan University, Hong Kong, China
40	Email: gary.tse@kmms.ac.uk NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

41 Prof. Jiandong Zhou, PhD

- 42 Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The
- 43 University of Hong Kong, Hong Kong, China
- 44 Division of Health Science, Warwick Medical School, University of Warwick, United Kingdom
- 45 Email: <u>Jiandong.Zhou@warwick.ac.uk</u>
- 46
- 47

48 Abstract

Introduction: Nasopharyngeal carcinoma (NPC) remains endemic in Asian regions, which risk factors were distinct from other head and neck (H&N) cancers. Anti-diabetic drugs has been proposed to reduce the risk of NPC. The associations between sodium glucose cotransporter 2 inhibitors (SGLT2I) versus dipeptidyl peptidase-4 inhibitors (DPP4I) and the risks of NPC and H&N cancer amongst type-2 diabetes mellitus (T2DM) patients remains unknown.

54 **Method:** This was a retrospective population-based cohort study including T2DM patients 55 treated with either SGLT2I or DPP4I between 1st January 2015 and 31st December 2019 in 56 Hong Kong. The primary outcome was new-onset NPC and other H&N cancer. The secondary 57 outcome was cancer-related mortality. Propensity score matching (1:1 ratio) was performed 58 using the nearest neighbour search. Multivariable Cox regression was applied to identify 59 significant predictors.

60 Results: This cohort included 75,884 patients with T2DM, amongst whom 28,778 patients 61 were on SGLT2I and 47,106 patients were on DPP4I. After matching (57556 patients), 106 62 patients developed NPC (0.18%), and 50 patients developed H&N cancer (0.08%). Compared to DPP4I, SGLT2I was associated with significantly lower risks of NPC (Hazard ratio [HR]: 0.41; 63 64 95% Confidence interval [CI]: 0.21-0.81) but not H&N cancer (HR: 1.00; 95% CI: 0.26-3.92) 65 after adjustments. The result remained significant regardless of demographics and obesity. The association remained consistent in different risk models, matching approaches, and the 66 67 sensitivity analysis.

68 Conclusion: This study provides real-world evidence that SGLT2I was associated with lower
69 risks of NPC, but not H&N cancer compared to DPP4I after adjustments amongst T2DM
70 patients.

71

- 72 Keywords: Sodium glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors,
- 73 Nasopharyngeal cancer, head and neck cancer, cancer, type-2 diabetes

74 Introduction

75 Nasopharyngeal carcinoma (NPC) remains as major public health challenge due to 76 their prevalence and mortality rate, especially in many Asian countries, with a reported incidence up to 50 per 100,000 population.¹ This is in contrast to the prevalence of NPC in 77 78 the Western countries which has a prevalence of less than 1 per 100. In general, head and 79 neck (H&N) cancer are tumours derived from the mucosa of the aerodigestive tract from the nasal cavity to the larynx.² One of the most important H&N cancer is NPC. NPC has a distinct 80 81 epidemiology, aetiology and pathological characteristics compared to other H&N cancer.³ 82 NPC is endemic in the southern region of China, as well as other parts of east and southeast Asia.⁴ Epstein-Barr virus (EBV) infection remained as the centre of the pathogenesis of NPC. 83 84 Lifestyle and diet habits such as consuming preserved food which is more likely to be practised by Chinese population and smoking may become another potential risk factors for NPC.⁵ Since 85 86 most patients with NPC are diagnosed with late-stage disease, and that patients diagnosed 87 with metastatic NPC have poor prognosis, there remains to be a need for preventing the risks of new-onset NPC.6 88

Anti-diabetic drugs has been described in reducing the risk of NPC. In a Taiwan study, 89 90 metformin was associated with a significantly lower risks of NPC compared to metformin non-91 user amongst T2DM patients.⁷ Sodium glucose cotransporter 2 inhibitors (SGLT2I) has 92 demonstrated extensive anti-cancer effects across various malignancy, such that SGLT2I was associated with a reduced risks of cancer compared to placebo or other anti-diabetic drugs.8-93 94 ¹⁰ EBV-encoded oncoprotein latent membrane protein 1 (LMP1) may increase the level of 95 glucose transporter 1 and therefore enhance glucose uptake by the NPC cells and drives the Warburg effect.^{6, 11} As such, SGLT2I might have help prevent NPC by playing its role in the 96 97 metabolic reprogramming. However, the effects of SGLT2I on NPC on a population scale

98 remained uncertain. However, the association between other second-line anti-diabetic drugs 99 such as SGLT2I and) dipeptidyl peptidase-4 inhibitors (DPP4I) remained scarce. 100 Since NPC remains endemic in Hong Kong, using the territory's electronic health 101 record data allows studying the association between SGLT2I and NPC using a data with large 102 sample size, which is unlikely to be completed using a prospective study or randomised 103 controlled trials.¹² Hence, this study aimed to investigate the role of SGLT2I and DPP4I with 104 new-onset NPC and H&N cancer in a cohort of T2DM patients from a territory-wide population cohort study. 105

106

107 Methods

108 This study was approved by the Institutional Review Board of the University of Hong 109 Kong/Hospital Authority Hong Kong West Cluster (HKU/HA HKWC IRB) (UW-20-250) and 110 complied with the Declaration of Helsinki.

111

112 Study design and population

113 This was a retrospective, territory-wide cohort study of T2DM patients who received 114 their treatment with SGLT2I or DPP4I between 1st January 2015, and 31st December 2019, in Hong Kong. The follow-up period is continued until 31st December 2020, or until the patients' 115 116 demise. A sensitivity analysis that included a cohort of patients on glucagon-like peptide-1 117 receptor agonist (GLP1a) between 1st January 2015 and 31st December 2019 was conducted 118 to elucidate the relative effects among the second-line oral antidiabetic medications. The 119 patients were identified from the Clinical Data Analysis and Reporting System (CDARS), a 120 territory-wide database that centralizes patient information from individual local hospitals to 121 establish comprehensive medical data, including clinical characteristics, disease diagnosis, 122 laboratory results, and drug treatment details. The system has been used by local teams in Hong Kong to conduct comparative studies.¹³⁻¹⁵ The exclusion criteria of the study involved 123 124 patients: 1) With prior NPC or H&N cancer 2) Without complete demographics 3) Under 18 125 years old (Figure 1). This study employed an as-treat approach, including the censoring of 126 patients at the discontinuation of treatment or switching between the comparison 127 medications.

The demographic details of the patients, including gender and age at the initiation of drug use (baseline), clinical diagnoses and laboratory results as well as medications were extracted for this study. International Classification of Diseases Ninth Edition (ICD-9) codes

131 (Supplementary Table 1) were used to identify the prior comorbidities. Financial aid patients 132 were defined based on their participation in the Comprehensive Social Security Assistance 133 (CSSA) scheme, higher disability allowance, normal disability allowance, waiver and other 134 financial aid in Hong Kong. Charlson's standard comorbidity index and the duration and 135 frequency of SGLT2I and DPP4I usage were calculated. To calculate the diabetes duration, the 136 earliest date was examined by the first date of (1) diagnosis using ICD-9; (2) Hba1c \geq 6.5%; (3) Fasting glucose≥7.0 mmol/l or Random glucose 11.1 mmol/l; (4) using antidiabetic drugs. The 137 138 estimated glomerular filtration rate (eGFR) was computed using the abbreviated modification 139 of diet in renal disease (MDRD) formula.¹⁶

140

141 Adverse outcomes

142 The primary outcome of this study was new-onset NPC (ICD-9: 147) and H&N cancer other than NPC (ICD-9: 140-149, 160-161, excluding 147).¹⁷ Mortality data were obtained 143 144 from the Hong Kong Death Registry, an official government registry with the registered death records of all Hong Kong citizens linked to CDARS. Mortality was recorded according to the 145 146 International Classification of Diseases Tenth Edition (ICD-10). The endpoint date of interest 147 for eligible patients was the primary outcome presentation date. The endpoint for those without primary outcome was the mortality date or the endpoint of the study, which is 31st 148 149 December 2020.

150

151 Statistical analysis

152 Descriptive statistics are used to outline the baseline clinical and biochemical 153 characteristics of patients using SGLT2I and DPP4I. The continuous variable for baseline

154 clinical features was expressed as the mean (95% confidence interval/standard deviation [SD]) 155 while the total number (percentage) represented the categorical variables. The two-tailed 156 Mann-Whitney U test was utilised to make a comparison between the continuous variables, 157 whereas the two-tailed Chi-square test with Yates' correction was applied for 2x2 contingency 158 data. Propensity score matching with 1:1 ratio for SGLT2I use versus DPP4I use based on 159 demographics, prior comorbidities, number of prior hospitalisation, duration from T2DM 160 diagnosis initial drug exposure, non-SGLT2I/DPP4I medications, abbreviated MDRD, time-161 weighted HbA1c, and time-weighted fasting glucose were performed using the nearest 162 neighbour search strategy with a calliper of 0.1. Stata software (Version 16.0) was used in 163 facilitating the propensity score matching procedures.

164 In this study, we assessed the comparison of the baseline characteristics of patients 165 before and after consuming SGLT2I and DPP4I with standardized mean difference (SMD), 166 where SMD<0.10 was considered as indicative of well-balanced between the two groups. A Cox proportional hazards regression model was performed to identify significant risk 167 168 predictors of adverse study outcomes. Adjustments were made for the demographics, past 169 comorbidities, duration of diabetes mellitus, and number of prior hospitalizations, number of 170 anti-diabetic drugs, non-SGLT2I/DPP4I medications, abbreviated MDRD, HbA1c, fasting glucose, lipid profile. To verify the proportionality assumption for the model mentioned above, 171 172 the log-log plot was established. The cumulative incidence curves were generated for both 173 primary and secondary outcomes and the subgroup analysis was undertaken for the 174 affirmation of the association among patients with pivotal clinical predictors. Pinteraction was 175 applied to examine the differences in the associations between the subgroups.

176 To account for the potential competing risks in this study, cause-specific and sub-177 distribution hazard models were also carried out. Multiple propensity score methodologies were implemented, encompassing propensity score stratification,¹⁸ propensity score with 178 inverse probability of treatment weighting (IPTW)¹⁹ and propensity score with stable inverse 179 180 probability weighting ²⁰. We also performed a sensitivity analysis to examine the impacts of 181 the various minimum drug duration on the outcome. The contraindication of the use of 182 SGLT2I included patients with CKD stage 4/5 (eGFR <30 mL/min/1.73m^2), peritoneal dialysis 183 or haemodialysis recipients and thus being excluded for the above analysis. Besides, the 184 exclusion criteria were also included: (1) patients who have primary immunodeficiency; (2) Lag time of 6 months, 1 year and 2 years; (3) 10% propensity score at the 2 ends. 185

186 To evaluate the relationship and preference amongst the three novel second-line 187 antidiabetic drugs, the three-arm sensitivity analysis involving GLP1a using stabilized IPTW 188 was performed. As part of a falsification analysis to detect residual bias and confounding 189 factors arising from unobserved variables, a negative control outcome was introduced. To be 190 specified, lower limb fractures (ICD-9 codes: 820-829) were utilized in the falsification analysis. 191 Any observed significant association in this context was interpreted as likely stemming from 192 bias rather than a genuine effect. The final results were demonstrated in terms of hazard ratio 193 (HR), 95% CI and P-value. Statistical significance was defined as P-value < 0.05. All statistical analyses were executed with RStudio software (Version: 1.1.456) and Python (Version: 3.6). 194

195

196 Results

197 Baseline characteristics

198 In this territory-wide cohort study of 76,147 patients with T2DM treated with 199 SGLT2I/DPP4I between 1st January 2015 and 31st December 2019 in Hong Kong, patients 200 were followed up until 31st December 2020 or their deaths (Figure 1). The following patient 201 groups were excluded: (1) with prior NPC or H&N cancer (N=113); (2) without complete 202 demographics (N=19); (3) under 18 years old (N=108). After exclusion, this study included a 203 total of 75,884 patients with T2DM (mean age: 62.4 years old [Standard deviation: 12.8]; 204 55.77% males), of whom 28,778 patients used SGLT2Is, and 47,106patients used DPP4Is 205 (Table 1). Before matching, the SGLT2 users had higher numbers of male patients, were 206 younger, had lower Charlson's standard comorbidity index, and had more cases of 207 hypertension, use of anti-diabetic drugs, anti-hypertensive drugs and lipid-lowering drugs, 208 and a higher eGFR compared to DPP4I users. The characteristics of patients are shown in 209 Table 1.

210 After the propensity score matching, baseline characteristics and the time-weighted 211 lipid and glucose profiles of the 2 groups were well-balanced, apart from baseline age 212 (SMD=0.14), number of hospitalizations (SMD=0.12), thiazolidinedione (SMD=0.13), and 213 abbreviated MDRD (SMD=0.11) (Table 1). The DPP4I and SGLT2I cohorts were comparable 214 after matching with nearest neighbour search strategy with calliper of 0.1, and the 215 proportional hazard assumption was confirmed (Supplementary Figure 1). In the matched 216 cohort, 106 patients developed NPC, 50 patients developed H&N cancer, 899 patients passed 217 away due to cancer during the study period (Figure 1).

218

219 The association between SGLT2I and the primary outcomes

220	In the matched cohort, 31 SGLT2I users and 75 DPP4I users developed NPC. After a
221	mean follow-up of 314,709.1 person-year, the incidence of NPC was lower amongst SGLT2I
222	users (Incidence rate [IR] per 100,000 person-year: 19.43; 95% CI: 13.20-27.58) compared to
223	DPP4I users (IR per 100,000 person-year: 48.33; 95% CI: 38.02-60.58) (Table 2). Compared to
224	DPP4I users, SGLT2I users had a 59% lower risk of NPC after adjustment (Hazard ratio [HR]:
225	0.41; 95% Confidence Interval [CI]: 0.21-0.81) for demographics, past comorbidities, duration
226	of diabetes mellitus, and number of prior hospitalizations, number of anti-diabetic drugs, non-
227	SGLT2I/DPP4I medications, abbreviated MDRD, HbA1c, fasting glucose, lipid profile. (Table 2).
228	This was substantiated by the cumulative incidence curves stratified by SGLT2I versus DPP4I
229	(Figure 2).

Meanwhile, 20 SGLT2I users and 30 DPP4I users developed H&N cancer. After a mean follow-up of 314,893.5 person-year, the incidence of NPC was lower amongst SGLT2I users (IR per 100,000 person-year: 12.53; 95% CI: 7.66-19.36) compared to DPP4I users (IR per 100,000 person-year: 19.32; 95% CI: 13.03-27.58) **(Table 2)**. SGLT2I users was not associated with H&N cancer (HR: 1.00; 95% CI: 0.26-3.92) compared to users of DPP4I after adjustment **(Table 2)**.

235

236 The association between SGLT2I and cancer-related mortality

180 SGLT2I users and 719 DPP4I users died. After a follow-up of 315,010.8 personyear, the incidence of cancer-related mortality was lower amongst SGLT2I users (IR: 112.76;
95% CI: 96.89-130.49) compared to DPP4I users (IR: 462.74; 95% CI: 429.53-497.84) (Table 2).
SGLT2I users had a lower risk of cancer-related mortality after adjustment (HR: 0.42; 95% CI:
0.29-0.60) compared to users of DPP4I. This was substantiated by the cumulative incidence
curves stratified by SGLT2I versus DPP4I (Figure 2).

243

244 Subgroup analysis

245 The results of the subgroup analysis for effects of SGLT2I and DPP4I on the NPC are 246 shown in Figure 3. The result demonstrated that SGLT2I was associated with lower risks of NPC regardless of sex, age, socioeconomic status, renal disease, and obesity. Besides, the 247 248 effects of SGLT2I on NPC were not affected by presence of baseline cancer, autoimmune 249 disease, systemic steroid use, or immunosuppressant/chemotherapy use. The marginal 250 effects analysis demonstrated that SGLT2I use was associated with lower risks of NPC 251 regardless the duration of diabetes (Supplementary Figure 2). However, SGLT2I was 252 associated with lower risks of NPC compared to DPP4I only amongst patient with poorer renal 253 function and higher time-weighted mean of HbA1c. Meanwhile, SGLT2I was associated with lower risks of H&N cancer regardless of the time-weighted mean of HbA1c, but only amongst 254 255 patients with short duration of diabetes, poorer renal function.

256

257 Sensitivity analyses

258 Sensitivity analyses were performed to confirm the predictability of the models. The results of the cause-specific hazard models, sub-distribution hazard models and different 259 260 propensity score approaches demonstrated that different models did not change association 261 for both the primary and the secondary outcomes (Supplementary Table 2). A three-arm 262 analysis with the inclusion of GLP1a including patients only on (SGLT2I, DPP4I, and GLP1a) 263 using stabilized IPTW was conducted (Supplementary Table 3). While SGLT2I was also associated with higher risks of NPC compared to GLP1a, the results remained insignificant due 264 265 to the insufficient power in the GLP1a cohort (HR: 1.24; 95% CI: 0.79-1.66). Besides, SGLT21

266 also did not associated with a lower risk of cancer-related mortality compared to GLP1a (HR: 267 1.09; 95% CI: 0.56-1.95). The sensitivity analysis for 6 months, 1-year and 2-year lag time 268 demonstrated the same pattern. Besides, after excluding patients with extreme 10% 269 propensity score at the 2 end, patients with CKD stage 4/5 (eGFR <30), peritoneal dialysis or 270 haemodialysis, and patients with primary immunodeficiency likewise, the results demonstrated that SGLT2I remained associated with lower risks of NPC compared to DPP4I 271 (Supplementary Table 4). 272 273 274 Falsification analysis 275 Lower limb fracture was used as negative control outcome in the falsification analysis 276 for the comparison between SGLT2I and DPP4I since most of the cases should be traumatic 277 cause (Supplementary Table 9). The results demonstrated that SGLT2I was not associated 278 with lower limb fracture after adjustment (HR: 1.29; 95% CI: 00.95-1.79) compared to DPP4I. 279 280 Discussion 281 In this territory-wide cohort study, the associations between SGLT2I, DPP4I and new-282 onset NPC and H&N were examined using real-world data. Our results firstly demonstrate 283 that SGLT2I use was independently associated with a lowered risk of new-onset NPC than 284 DPP4I usage after adjustments. Secondly, SGLT2I was not associated with lower risks of H&N 285 cancer compared to DPP4I. The results remained consistent across different competing risk 286 and the sensitivity analyses, and the falsification analysis did not falsify the results. To the

287 best of our knowledge, this was the first cohort study to examine the association between

288 SGLT2I and NPC.

289

290 Comparison with previous studies

291 The incidence of NPC in our study for SGLT2I and for DPP4I parallels the values of existing study, with a reported incidence of 15-50 per 100,000 population.¹ NPC is endemic in 292 Southern China, as well as other parts of South-East Asia.²¹ In Hong Kong, a previous study 293 294 described an incidence of 10.1 per 100,000 in male and 3.3 per 100,000 in female in 2020.²² 295 Previously, SGLT2I was proposed as an potential anti-tumour agents since sodium-glucose 296 cotransporter 2 was over-expressed in multiple tumour models, including head and neck cancer.^{23, 24} In this study, we found that SGLT2I was associated with lower risk of NPC 297 compared to DPP4I. 298

299 Previously, metformin was reported to be associated with a lower risk of NPC compared to metformin non-user.^{7, 25 26} However, the effects of the anti-diabetic drugs on 300 NPC might be independent of their ability of glycaemic control. Previously, a meta-analysis 301 302 identified that T2DM patients might have decreased risk of NPC amongst the Asian population. 303 This could be explained by the pathological phenotypes of undifferentiated NPC. It was found that the prevalence of T2DM in differentiated NPC was higher compared to undifferentiated 304 cases, such that T2DM may only effect on the former pathological subtype.²⁷ T2DM was also 305 306 reported not to be associated with mortality amongst NPC patients.²⁸ Meanwhile, in a 307 prospective cohort study in Taiwan, diabetic patients who received metformin had a lower 308 risk of developing H&N cancer compared to the matched individuals without metformin. Specifically, the incidence of oropharyngeal cancer and NPC was significantly lower for 309 patients treated with metformin than their counterparts.²⁹ Another study also supported a 310 311 reduced risk of H&N cancer for metformin, particularly with a history of smoking and heavy

drinking.²⁹ Apart from anti-diabetic medications, a Taiwan case-control study found that the risk of head and neck cancer is reduced by statin.³⁰ Several studies also demonstrated that patients received statin were associated with increased survival of head and neck cancer.^{31, 32} Hence, metabolic drugs might potentially be preventive for head and neck cancer.

316

317 Potential underlying mechanisms

318 SGLT2 inhibitors have recently reported to exhibit possible anti-cancer effects in 319 several malignancies. It was proposed that SGLT2I act to inhibit the active reverse transport of glucose by SGLT-2 located in the proximal renal tubule, which consequently affect the 320 cellular respiration and growth of the tumour cells.^{33 34} Our results suggested that the effects 321 322 of SGLT2I mainly targeted specifically on NPC but not H&N cancer in general. Besides, SGLT2I 323 may act on the LMP1 induced glucose transporter 1 which reduce glucose uptake by the NPC cells.^{6, 11} Meanwhile, DPP4I were hypothesized to diminish the cancer risk by eliminating the 324 degradation of incretins, glucagon-like peptide-1 (GLP-1) and glucose-dependent 325 insulinotropic peptide (GIP) in the cell.³⁵ Although there are multiple studies regarding both 326 327 SGLT2 inhibitors and DPP4 inhibitors act on cancer, the mechanism of both medications 328 towards head and neck cancer, especially NPC, remains unclear.

329

330 Clinical implications

The secondary protective benefits of SGLT2I and DPP4I on cardiovascular benefits and cancer have received worldwide attention in recent years. While there is substantial evidence supporting the effects of the anti-diabetic medications on cardiovascular diseases ³⁶, few evidence surrounding the latter. By exploring the association of SGLT2I and DPP4I in HCCNPC

this study added to the growing body of evidence supporting the use of antidiabetic agents in
preventing cancer. However, further molecular studies and clinical studies are needed to
confirm the causation relationship between SGLT2I and NPC.

338

339 Limitations

340 Several limitations should be acknowledged in this study. First of all, the observational 341 nature of this study gives inherent issues such as under-coding, coding errors, and missing 342 data possibly resulting in information bias. Crucial data on predictive variables, for instance, 343 nitrosamine consumption, diet, and family history of NPC were unavailable from CDARS. In 344 addition, the inclusion of patients in CDARS was only limited to those who smoked, consumed 345 alcohol, and were obese to a degree that required medical attention and treatment. To 346 mitigate this limitation, this study incorporated extensive comorbidities related to NPC to 347 indirectly infer the possible risk variables. Furthermore, a falsification analysis was also 348 conducted to minimise the risk of residual confounding. Moreover, the retrospective design allows only for the inference of associations but not the demonstration of causation 349 350 relationships. Lastly, assessing medication adherence relied solely on prescription refills, 351 lacking direct measurement of drug exposure. This approach may lead to time lag biases and 352 immortal time issues. Hence, it is essential to conduct prospective randomised controlled 353 trials aimed at evaluating the causal links of anti-diabetic medications.

354

355 Conclusion

356	In this population-based cohort study, SGLT2I users was associated with lower risks of
357	NPC but not H&N cancer compared to DPP4I users after matching and adjustments compared
358	to DPP4I users in Asia. Future studies are needed about the SGLT2I and its action on NPC.
359	
360	Ethical approval statement
361	This study was approved by the Institutional Review Board of the University of Hong
362	Kong/Hospital Authority Hong Kong West Cluster (HKU/HA HKWC IRB) (UW-20-250) and
363	complied with the Declaration of Helsinki.
364	
365	Availability of data and materials
366	The data that support the findings of this study were provided by the Hong Kong Hospital
367	Authority, but restrictions apply to the availability of these data, which were used under
368	license for the current study, and so are not publicly available. Data are however available
369	from the authors upon reasonable request and with permission of Hong Kong Hospital
370	Authority.
371	
372	Conflicts of Interest
373	None.
374	
375	Acknowledgements

- 376 Oscar Hou In Chou and Kar Kei Mak would like to thank Bai Xian Asia Institute (BXAI) for her
- 377 generosity in providing Asian Future Leaders Scholarship Program scholarship.
- 378
- 379 Funding
- 380 This research received no specific grant from any funding agency in the public, commercial,
- 381 or not-for-profit sectors.
- 382
- 383 Guarantor Statement
- All authors approved the final version of the manuscript. GT is the guarantor of this work and,
- as such, had full access to all the data in the study and takes responsibility for the integrity of
- the data and the accuracy of the data analysis.
- 387

388 Author contributions

389 LF L, OHI C, JD Z: conception of study, preparation of figures, study design, data contribution,

390 statistical analysis, data interpretation, manuscript drafting, and critical revision of the391 manuscript.

- 392 OHI C, KK M, YF Y, CT C: literature search, data interpretation, literature search, data collection,
- 393 manuscript drafting.
- 394 GL L, C C, WT W, T L, BMY C: critical revision of the manuscript
- 395 G T, JD Z: conception of study and literature search, study design, data collection, and critical
- 396 revision of manuscript, study supervision.

References

1. Mahdavifar N, Ghoncheh M, Mohammadian-Hafshejani A, Khosravi B, Salehiniya H. Epidemiology and Inequality in the Incidence and Mortality of Nasopharynx Cancer in Asia. *Osong Public Health and Research Perspectives.* 2016;7(6): 360-372.

https://doi.org/https://doi.org/10.1016/j.phrp.2016.11.002.

Getz KR, Bellile E, Zarins KR, et al. Statin use and head and neck squamous cell 2. carcinoma outcomes. Int J Cancer. 2021;148(10): 2440-2448. https://doi.org/10.1002/ijc.33441.

3. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15(10): 1765-1777. https://doi.org/10.1158/1055-9965.Epi-06-0353.

Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol. 4. 2002;12(6): 421-429. https://doi.org/10.1016/s1044579x02000858.

5. Tsao SW, Yip YL, Tsang CM, et al. Etiological factors of nasopharyngeal carcinoma. Oral Oncol. 2014;50(5): 330-338. <u>https://doi.org/10.1016/j.oraloncology.2014.02.006</u>.

6. Liu Q, Bode AM, Chen X, Luo X. Metabolic reprogramming in nasopharyngeal carcinoma: Mechanisms and therapeutic opportunities. *Biochimica et Biophysica Acta (BBA)* - Reviews on Cancer. 2023;1878(6): 189023.

https://doi.org/https://doi.org/10.1016/j.bbcan.2023.189023.

7. Tseng C-H. Metformin and risk of developing nasopharyngeal cancer in patients with type 2 diabetes mellitus. Metabolism. 2018;85: 223-226.

https://doi.org/https://doi.org/10.1016/j.metabol.2018.04.009.

Benedetti R, Benincasa G, Glass K, et al. Effects of novel SGLT2 inhibitors on cancer 8. incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials. Pharmacological Research. 2022;175: 106039.

https://doi.org/https://doi.org/10.1016/j.phrs.2021.106039.

Oscar Hou In C, Jing N, Raymond Ngai Chiu C, et al. Lower risks of sodium glucose 9. cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for new-onset non-alcoholic fatty liver disease and hepatocellular carcinoma in type 2 diabetes mellitus: A population-based study. medRxiv. 2022: 2022.2008.2016.22278847. https://doi.org/10.1101/2022.08.16.22278847.

Chung CT, Lakhani I, Chou OHI, et al. Sodium-glucose cotransporter 2 inhibitors 10. versus dipeptidyl peptidase 4 inhibitors on new-onset overall cancer in Type 2 diabetes mellitus: A population-based study. Cancer Med. 2023;12(11): 12299-12315. https://doi.org/10.1002/cam4.5927.

11. Zhang J, Jia L, Lin W, et al. Epstein-Barr Virus-Encoded Latent Membrane Protein 1 Upregulates Glucose Transporter 1 Transcription via the mTORC1/NF-κB Signaling Pathways. J Virol. 2017;91(6). https://doi.org/10.1128/jvi.02168-16.

Rudrapatna VA, Glicksberg BS, Butte AJ. Utility of routinely collected electronic 12. health records data to support effectiveness evaluations in inflammatory bowel disease: a pilot study of tofacitinib. BMJ Health Care Inform. 2021;28(1). https://doi.org/10.1136/bmjhci-2021-100337.

13. Gao X, Zhang N, Lu L, et al. New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study. European Heart Journal - Cardiovascular Pharmacotherapy. 2023: pvad086. https://doi.org/10.1093/ehjcvp/pvad086.

14. Chou OHI, Zhou J, V Mui J, et al. Lower risks of new-onset acute pancreatitis and pancreatic cancer in sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors: A propensity score-matched study with competing risk analysis. Diabetes Epidemiology and Management. 2023;9: 100115. https://doi.org/https://doi.org/10.1016/j.deman.2022.100115.

Lee TTL, Chan SCL, Chou OHI, et al. Initiation of warfarin is associated with decreased 15. mortality in patients with infective endocarditis: A population-based cohort study. Thromb Res. 2023;233: 1-9. https://doi.org/10.1016/j.thromres.2023.11.009.

Soliman AR, Fathy A, Khashab S, Shaheen N. Comparison of abbreviated modification 16. of diet in renal disease formula (aMDRD) and the Cockroft-Gault adjusted for body surface (aCG) equations in stable renal transplant patients and living kidney donors. Ren Fail. 2013;35(1): 94-97. https://doi.org/10.3109/0886022x.2012.731970.

17. Chen MC, Feng IJ, Lu CH, et al. The incidence and risk of second primary cancers in patients with nasopharyngeal carcinoma: a population-based study in Taiwan over a 25-year period (1979-2003). Ann Oncol. 2008;19(6): 1180-1186.

https://doi.org/10.1093/annonc/mdn003.

Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of 18. Confounding in Observational Studies. Multivariate Behav Res. 2011;46(3): 399-424. https://doi.org/10.1080/00273171.2011.568786.

19. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28): 3661-3679.

https://doi.org/10.1002/sim.6607.

Avagyan V, Vansteelandt S. Stable inverse probability weighting estimation for 20. longitudinal studies. Scandinavian Journal of Statistics. 2021;48(3): 1046-1067. https://doi.org/https://doi.org/10.1111/sjos.12542.

Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. 21. Lancet. 2019;394(10192): 64-80. https://doi.org/10.1016/s0140-6736(19)30956-0.

22. Wang X, Sun H, Li L, Gan Z, Wu X, Du J. Changing patterns of nasopharyngeal carcinoma incidence in Hong Kong: a 30-year analysis and future projections. BMC Cancer. 2023;23(1): 761. https://doi.org/10.1186/s12885-023-11296-1.

Basak D, Gamez D, Deb S. SGLT2 Inhibitors as Potential Anticancer Agents. 23. Biomedicines. 2023;11(7). https://doi.org/10.3390/biomedicines11071867.

Wang Y, Mang X, Li D, et al. Cold atmospheric plasma sensitizes head and neck 24. cancer to chemotherapy and immune checkpoint blockade therapy. Redox Biology. 2024;69: 102991. https://doi.org/https://doi.org/10.1016/j.redox.2023.102991.

Li H, Chen X, Yu Y, et al. Metformin inhibits the growth of nasopharyngeal carcinoma 25. cells and sensitizes the cells to radiation via inhibition of the DNA damage repair pathway. Oncol Rep. 2014;32(6): 2596-2604. https://doi.org/10.3892/or.2014.3485.

Yen YC, Lin C, Lin SW, Lin YS, Weng SF. Effect of metformin on the incidence of head 26. and neck cancer in diabetics. Head Neck. 2015;37(9): 1268-1273. https://doi.org/10.1002/hed.23743.

27. Zucchetto A, Taborelli M, Bosetti C, et al. Metabolic disorders and the risk of nasopharyngeal carcinoma: a case-control study in Italy. Eur J Cancer Prev. 2018;27(2): 180-183. https://doi.org/10.1097/cej.00000000000286.

28. Peng H, Chen L, Zhang Y, et al. Prognostic value of Diabetes in Patients with Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiation Therapy. *Scientific*

Reports. 2016;6(1): 22200. https://doi.org/10.1038/srep22200.

29. Figueiredo RA, Weiderpass E, Tajara EH, et al. Diabetes mellitus, metformin and head and neck cancer. *Oral Oncol.* 2016;61: 47-54.

https://doi.org/10.1016/j.oraloncology.2016.08.006.

30. Kao LT, Hung SH, Kao PF, Liu JC, Lin HC. Inverse association between statin use and head and neck cancer: Population-based case-control study in Han population. *Head Neck*. 2019;41(5): 1193-1198. <u>https://doi.org/10.1002/hed.25501</u>.

31. Gupta A, Stokes W, Eguchi M, et al. Statin use associated with improved overall and cancer specific survival in patients with head and neck cancer. *Oral Oncol.* 2019;90: 54-66. <u>https://doi.org/10.1016/j.oraloncology.2019.01.019</u>.

32. Lebo NL, Griffiths R, Hall S, Dimitroulakos J, Johnson-Obaseki S. Effect of statin use on oncologic outcomes in head and neck squamous cell carcinoma. *Head Neck*. 2018;40(8): 1697-1706. <u>https://doi.org/10.1002/hed.25152</u>.

33. Dutka M, Bobiński R, Francuz T, et al. SGLT-2 Inhibitors in Cancer Treatment-Mechanisms of Action and Emerging New Perspectives. *Cancers (Basel).* 2022;14(23). <u>https://doi.org/10.3390/cancers14235811</u>.

34. Nasiri AR, Rodrigues MR, Li Z, Leitner BP, Perry RJ. SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia. *Cancer & Metabolism.* 2019;7(1): 10. https://doi.org/10.1186/s40170-019-0203-1.

35. Zhao M, Chen J, Yuan Y, et al. Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. *Scientific Reports.* 2017;7(1): 8273. <u>https://doi.org/10.1038/s41598-017-07921-2</u>.

36. McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis. *JAMA Cardiol.* 2021;6(2): 148-158. <u>https://doi.org/10.1001/jamacardio.2020.4511</u>.



Figure 1. Procedures of data processing

SGLT2I: Sodium-glucose cotransporter-2 inhibitors; DPP4I: Dipeptidyl peptidase-4 inhibitors; AMDRD: abbreviated modification of diet in renal disease.





New onset salivary gland and other head/neck cancer



Cumulative incidence curve by drug use after propensity score matching



All-cause mortality

Figure 2. Cumulative incidence curves for new onset NPC, other H&N cancer, cancerrelated mortality, and all-cause mortality stratified by drug exposure of SGLT2I and DPP4I after propensity score matching (1:1)

SGLT2I: Sodium-glucose cotransporter-2 inhibitors; DPP4I: Dipeptidyl peptidase-4 inhibitors. NPC: nasopharyngeal carcinoma; H&N: head and neck.



Figure 3. Subgroup analyses for SGLT2I v.s. DPP4I exposure predict new onset NPC in the matched cohort.

* For $p \le 0.05$, ** for $p \le 0.01$, *** for $p \le 0.001$; CI: confidence interval; SGLT2I: Sodium-glucose cotransporter-2 inhibitors; DPP4I: Dipeptidyl peptidase-4 inhibitors; HR: Hazard ratio; NPC: nasopharyngeal carcinoma.

Table 1. Baseline and clinical characteristics of patients with SGLT2I v.s. DPP4I use before and after propensity score matching (1:1).

* for SMD \geq 0.1; SGLT2I: sodium glucose cotransporter-2 inhibitor; DPP4I: dipeptidyl peptidase-4 inhibitor; MDRD: modification of diet in renal disease;

	Before matching				After matching			
Characteristics	All (N=75884) Mean(SD);N or Count(%)	SGLT2I users (N=28778) Mean(SD);N or Count(%)	DPP4I users (N=47106) Mean(SD);N or Count(%)	SM D	All (N=57556) Mean(SD);N or Count(%)	SGLT2I users (N=28778) Mean(SD);N or Count(%)	DPP4I users (N=28778) Mean(SD);N or Count(%)	SM D
Demographics				0.1				0.0
Male gender	42323(55.77%)	17127(59.51%)	25196(53.48%)	0.1	34610(60.13%)	17127(59.51%)	17483(60.75%)	0.0 3
Female gender	33561(44.22%)	11651(40.48%)	21910(46.51%)	0.1 2	22946(39.86%)	11651(40.48%)	11295(39.24%)	0.0 3
Baseline age, years	62.4(12.8);n=75 884	57.9(11.3);n=28 778	65.1(12.9);n=47 106	0.6 *	58.7(11.2);n=57 556	57.9(11.3);n=28 778	59.5(11.0);n=28 778	0.1 4*
Financial aid	2790(3.67%)	1167(4.05%)	1623(3.44%)	0.0 3	2256(3.91%)	1167(4.05%)	1089(3.78%)	0.0 1
Past comorbidities								
Charlson's standard comorbidity index medRxiv preprint doi: https://doi.org/10.1101/2024.0 preprint (which was not certified by peer review Duration from earliest diabetes	2.0(1.5);n=7588 21 4 4.24301285; this ve b) is the author/funder, w b) 6.5(4.9)	1.6(1.3);n=2877 rs&n posted January 1 ho has granted medRx 6.49(4.87);n=28	2.3(1.6);n=4710 5,@024. The copyright iv a license to display t 6.53(4.97);n=47	0.5 ho3der fo he prepi 0.0	1.6(1.2);n=5755 pr⋼ tint in 6.4(4.7);n=5755	1.6(1.3);n=2877 8 6.5(4.9);n=2877	1.7(1.2);n=2877 8 6.3(4.6);n=2877	0.0 8 0.0
diagnosis date to baseline date, day	4	778	106	1	6	8	8	5
Number of hospitalizations	1.2(0.8);n=7588 4	1.3(1.1);n=2877 8	1.2(0.6);n=4710 6	0.1 7	1.3(1.0);n=5755 6	1.3(1.1);n=2877 8	1.2(0.8);n=2877 8	0.1 2*
Hyperlipidaemia	55285(72.85%)	21876(76.01%)	33409(70.92%)	0.1 2	43800(76.09%)	21876(76.01%)	21924(76.18%)	<0. 01
Hypertension	43161(56.87%)	19179(66.64%)	23982(50.91%)	0.3 2*	39318(68.31%)	19179(66.64%)	20139(69.98%)	0.0 7
Diabetic retinopathy	5309(6.99%)	1953(6.78%)	3356(7.12%)	0.0 1	3759(6.53%)	1953(6.78%)	1806(6.27%)	0.0 2
Diabetic nephropathy	934(1.23%)	172(0.59%)	762(1.61%)	0.1	343(0.59%)	172(0.59%)	171(0.59%)	<0. 01
Diabetic neuropathy	1842(2.42%)	680(2.36%)	1162(2.46%)	0.0 1	1343(2.33%)	680(2.36%)	663(2.30%)	<0. 01
Baseline cancer	1940(2.55%)	564(1.95%)	1376(2.92%)	0.0 6	1126(1.95%)	564(1.95%)	562(1.95%)	<0. 01
Renal diseases	6096(8.03%)	1536(5.33%)	4560(9.68%)	0.1 7	2995(5.20%)	1536(5.33%)	1459(5.06%)	0.0 1
Liver diseases	2369(3.12%)	1053(3.65%)	1316(2.79%)	0.0 5	2044(3.55%)	1053(3.65%)	991(3.44%)	0.0 1
Heart failure	2505(3.30%)	757(2.63%)	1748(3.71%)	0.0 6	1492(2.59%)	757(2.63%)	735(2.55%)	<0. 01
Acute myocardial infarction	2158(2.84%)	955(3.31%)	1203(2.55%)	0.0 5	1886(3.27%)	955(3.31%)	931(3.23%)	<0. 01
Ischemic heart disease	7860(10.35%)	3619(12.57%)	4241(9.00%)	0.1 2	6813(11.83%)	3619(12.57%)	3194(11.09%)	0.0 5
Atrial fibrillation	1979(2.60%)	656(2.27%)	1323(2.80%)	0.0 3	1300(2.25%)	656(2.27%)	644(2.23%)	<0. 01
Stroke/transient ischemic attack	2418(3.18%)	739(2.56%)	1679(3.56%)	0.0 6	1467(2.54%)	739(2.56%)	728(2.52%)	<0. 01
Autoimmune disease	809(1.06%)	312(1.08%)	497(1.05%)	<0. 01	618(1.07%)	312(1.08%)	306(1.06%)	<0. 01
HPV infection	128(0.16%)	45(0.15%)	83(0.17%)	<0. 01	90(0.15%)	45(0.15%)	45(0.15%)	<0. 01
Primary immunodeficiency	492(0.64%)	105(0.36%)	387(0.82%)	0.0 6	210(0.36%)	105(0.36%)	105(0.36%)	<0. 01
Overweight, obesity and hyperalimentation required treatment	576(0.75%)	421(1.46%)	155(0.32%)	0.1 2	827(1.43%)	421(1.46%)	406(1.41%)	<0. 01
Alcohol dependence required treatment	169(0.22%)	42(0.14%)	127(0.26%)	0.0 3	84(0.14%)	42(0.14%)	42(0.14%)	<0. 01
Tobacco dependence required treatment	1066(1.40%)	163(0.56%)	903(1.91%)	0.1 2	326(0.56%)	163(0.56%)	163(0.56%)	<0. 01
Number of anti-diabetic drug classes	3.4(0.9);n=7588 4	3.5(1.0);n=2877 8	3.4(0.8);n=4710 6	0.2	3.5(0.9);n=5755 6	3.55(0.96);n=28 778	3.55(0.91);n=28 778	<0. 01
Metformin	68140(89.79%)	26863(93.34%)	41277(87.62%)	0.2	53814(93.49%)	26863(93.34%)	26951(93.65%)	0.0 1
Sulphonylurea	58324(76.85%)	20695(71.91%)	37629(79.88%)	0.1 9	42438(73.73%)	20695(71.91%)	21743(75.55%)	0.0 8
Insulin	38694(50.99%)	14795(51.41%)	23899(50.73%)	0.0 1	29828(51.82%)	14795(51.41%)	15033(52.23%)	0.0 2
Acarbose	2043(2.69%)	1113(3.86%)	930(1.97%)	0.1 1	2135(3.70%)	1113(3.86%)	1022(3.55%)	0.0 2
Thiozolidinedone	15218(20.05%)	7849(27.27%)	7369(15.64%)	0.2 9*	14751(25.62%)	7849(27.27%)	6902(23.98%)	0.0 8

ACEI: angiotensin-converting enzyme inhibitors; ARB: angiotensin II receptor blockers.

Glucagon-like peptide-1 receptor agonists	2523(3.32%)	1967(6.83%)	556(1.18%)	0.2 9*	3670(6.37%)	1967(6.83%)	1703(5.91%)	0.0 4
ACEI/ARB	26842(35.37%)	10601(36.83%)	16241(34.47%)	0.0 5	22617(39.29%)	10601(36.83%)	12016(41.75%)	0.1
Diuretics	41874(55.18%)	20840(72.41%)	21034(44.65%)	0.5 9*	41039(71.30%)	20840(72.41%)	20199(70.18%)	0.0 5
Statins and fibrates	40813(53.78%)	18266(63.47%)	22547(47.86%)	0.3 2*	36160(62.82%)	18266(63.47%)	17894(62.17%)	0.0 3
Systemic steroids	434(0.57%)	306(1.06%)	128(0.27%)	0.1	602(1.04%)	306(1.06%)	296(1.02%)	<0. 01
Immunosuppressant and chemotherapy	2536(3.34%)	564(1.95%)	1972(4.18%)	0.1 3	1132(1.96%)	564(1.95%)	568(1.97%)	<0. 01
Calculated biomarkers								
Abbreviated MDRD, mL/min/1.73m^2	80.8(28.4);n=63 103	89.8(24.1);n=24 210	75.2(29.4);n=38 893	0.5 4*	86.6(25.8);n=48 318	89.8(24.1);n=24 210	86.5(27.0);n=24 108	0.1 1*
Lipid profiles								
Time weighted mean of triglyceride,	1.8(1.0);n=3885	1.9(1.0);n=1739	1.8(1.0);n=2146	0.0	1.9(1.0);n=3251	1.86(1.0);n=173	1.87(1.01);n=15	<0.
mmol/L	7	4	3	5	8	94	124	01
Time weighted mean of low-density	2.3(0.6);n=3648	2.3(0.56);n=162	2.34(0.59);n=20	0.0	2.3(0.6);n=3070	2.3(0.56);n=162	2.31(0.58);n=14	0.0
lipoprotein, mmol/L	8	68	220	7	1	68	433	1
Time weighted mean of high-density medRxiv preprint doi: https://doi.org/10.1101/2024.0 https://doi.org/10.1101/2024.0	1.2(0.2);n=3833 1.14.24301285; this ve) i \$ the author/funder, w	1.16(0.19);n=17 rsion posted January 1 /h 2.69 s granted medRx	1.18(0.21);n=21 5, 2024. The copyright iv@/i#ense to display th	0.0 holder f he pr 8 p	1.2(0.2);n=3229 or this find in	1.16(0.19);n=17 260	1.16(0.2);n=150 30	<0. 01
Time weighted mean of totalis made availab		44.3(0.6):n=1.742	4.4(0.6);n=2147	0.0	4.3(0.6);n=3256	4.3(0.6);n=1742	4.32(0.63);n=15	0.0
cholesterol, mmol/L	8	4	4	8	0	4	136	2
Glucose tests								
Time weighted mean of HhA1C %	7.9(1.4);n=4617	7.9(1.4);n=1983	7.8(1.4);n=2633	0.0	7.9(1.4);n=3826	7.9(1.4);n=1983	7.8(1.3);n=1843	0.0
Time weighted mean of fibAIC, %	4	5	9	6	7	5	2	5
Time weighted mean of fasting glucose,	7.8(3.0);n=4283	7.9(2.9);n=1857	7.8(3.0);n=2426	0.0	7.9(3.1);n=3530	7.9(2.9);n=1857	7.8(3.2);n=1673	0.0
mmol/L	9	6	3	3	9	6	3	2

Table 2. Incidence and multivariate Cox regression models of new onset NPC, other H&N cancer and cancer-related mortality in the cohort after 1:1 propensity score matching.

* For p≤ 0.05, ** for p ≤ 0.01, *** for p ≤ 0.001; CI: confidence interval; SGLT2I: sodium glucose cotransporter-2 inhibitor; DPP4I: dipeptidyl peptidase-4 inhibitor; IQR: Interquartile range.

Adjusted for significant demographics, past comorbidities, duration of diabetes mellitus, and number of prior hospitalizations, number of anti-diabetic drugs, non-SGLT2I/DPP4I medications, abbreviated MDRD, HbA1c, fasting glucose, lipid profile.

NPC	Number of patients	Number of events	Total person- year	Follow-up duration, year [IQR]	Incidence per 100,000 person-year [95% CI]	Adjusted hazard ratio [95% CI]	P-value
DPP4I	28778	75	155176.8	5.4[0.7]	48.33[38.02-60.58]	1 [Reference]	NA
SGLT2I	28778	31	159532.3	5.5[0.4]	19.43[13.20-27.58]	0.41[0.21-0.81]	0.0095**
Other H&N cancer	Number of patients	Number of events	Total person- year	Follow-up duration, year [IQR]	Incidence per 100,000 person-year [95% CI]	Adjusted hazard ratio [95% CI]	P value
DPP4I	28778	30	155306.8	5.4[0.7]	19.32[13.03-27.58]	1 [Reference]	NA
SGLT2I	28778	20	159586.7	5.5[0.4]	12.53[7.66-19.36]	1.00[0.26-3.92]	0.9985
Cancer-related mortality	Number of patients	Number of events	Total person- year	Follow-up duration, year [IQR]	Incidence per 100,000 person-year [95% CI]	Adjusted hazard ratio [95% CI]	P value
DPP4I	28778	719	155377.9	5.4[0.7]	462.74[429.53-497.84]	1 [Reference]	NA
SGLT2I	28778	180	159632.9	5.5[0.4]	112.76[96.89-130.49]	0.42[0.29-0.60]	<0.0001***

medRxiv preprint doi: https://doi.org/10.1101/2024.01.14.24301285; this version posted January 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.